Survival Is Poorer in Patients With Secondary Core-binding Factor Acute Myelogenous Leukemia Compared With De Novo Core-binding Factor Leukemia

BACKGROUND: Therapy related secondary acute myelogenous leukemia (AML) was commonly associated with prior exposure to alkylating agents or topoisomerase inhibitor. The long-term outcome of such patients with secondary AML was found to be worse than that of patients with de novo AML. Earlier reports...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Borthakur, Gautam, Lin, E, Jain, Nitin, Estey, Elihu E., Cortes, Jorge E., O'Brien, Susan, Faderl, Stefan, Ravandi, Farhad, Pierce, Sherry, Kantarjian, Hagop
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2009
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4184418/
https://ncbi.nlm.nih.gov/pubmed/19441109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.24367
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia